Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.

ABSTRACT:

Background

Panel sequencing, whole-exome sequencing (WES) and whole-genome sequencing (WGS) often uncover therapeutic targets for cancer patients. However, it is still largely unclear to what extent patients directly benefit from broader analyses over panel sequencing alone.

Materials and methods

We analyzed the molecular findings and recommendations issued by our molecular tumor board (MTB) in a cohort of patients who had received both a well-established diagnostic panel of medium size (up to 203 genes) and in-house WES, focusing on the number of recommendations that were issued on the basis of WES results only.

Results

Our cohort consisted of 38 patients with advanced cancers, of whom about two-thirds had common and one-third had rare cancers. They received a total

SUBMITTER: Krieghoff-Henning E 

PROVIDER: S-EPMC12689208 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature